Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02389946 · ClinicalTrials.gov registry record · NA
Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions
A NA study, sponsored by Biotronik.
- Completed
- Registry status
- NA
- Development phase
- 1,334
- Enrollment target
NCT02389946 is a NA study that has completed, run by Biotronik. The registered enrollment target is 1,334 participants.
The verdict
NCT02389946, a NA study, has completed, sponsored by Biotronik.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,334 participants
- Enrollment target
Study Summary
The objective of this study is to assess the safety and efficacy of the Orsiro Sirolimus Eluting Coronary Stent System in the treatment of subjects with up to three native de novo or restenotic (standard PTCA only) coronary artery lesions compared to the Xience coronary stent system.
Interventions
- DEVICE Xience DES
- DEVICE Orsiro DES
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,334 participants |
| Start Date | 2015-05 |
| Est. Completion | 2021-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02389946
The ClinicalTrials.gov registry entry for NCT02389946 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 1,334 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biotronik, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Xience DES is the first listed.
NCT02389946 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02389946 about?
NCT02389946 is a clinical study titled "Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions". The objective of this study is to assess the safety and efficacy of the Orsiro Sirolimus Eluting Coronary Stent System in the treatment of subjects with up to three native de novo or restenotic (standard PTCA only) coronary artery lesions compared to the Xience coronary stent system.
What is the current status of trial NCT02389946?
This trial is currently completed. It is a NA study. The enrollment target is 1,334 participants. The study started on 2015-05. Estimated completion is 2021-03.
What interventions are being tested in trial NCT02389946?
The interventions under investigation include: Xience DES (DEVICE), Orsiro DES (DEVICE).
Who is sponsoring clinical trial NCT02389946?
This trial is sponsored by Biotronik, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.